Log in to save to my catalogue

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9844551

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

About this item

Full title

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

Publisher

United States: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2022-03, Vol.386 (12), p.1132-1142

Language

English

Formats

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

Standard therapy for metastatic, hormone-sensitive prostate cancer is androgen-deprivation therapy, usually with docetaxel. A large, multinational, phase 3 trial assessed the addition of the androgen-receptor blocker darolutamide to standard therapy. At 4 years, survival was higher with darolutamide than with placebo (62.7% vs. 50.4%), with no majo...

Alternative Titles

Full title

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9844551

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9844551

Other Identifiers

ISSN

0028-4793,1533-4406

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2119115

How to access this item